AustralianSuper Pty Ltd Has $98.07 Million Holdings in Insulet Corporation $PODD

AustralianSuper Pty Ltd grew its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 54.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 317,658 shares of the medical instruments supplier’s stock after acquiring an additional 112,490 shares during the quarter. AustralianSuper Pty Ltd owned 0.45% of Insulet worth $98,071,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC increased its position in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Insulet by 10.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 3,332 shares of the medical instruments supplier’s stock worth $1,003,000 after buying an additional 304 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insulet by 5.8% during the second quarter. V Square Quantitative Management LLC now owns 1,930 shares of the medical instruments supplier’s stock worth $606,000 after buying an additional 106 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Insulet by 784.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 47,827 shares of the medical instruments supplier’s stock valued at $15,026,000 after acquiring an additional 42,422 shares during the last quarter. Finally, Arcadia Wealth Management LLC bought a new position in shares of Insulet in the 2nd quarter valued at $207,000.

Insulet Price Performance

Shares of NASDAQ PODD opened at $258.20 on Thursday. The company has a market capitalization of $18.16 billion, a PE ratio of 74.84, a P/E/G ratio of 1.48 and a beta of 1.40. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The firm has a fifty day simple moving average of $294.22 and a 200 day simple moving average of $309.62.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period last year, the business posted $1.08 EPS. The business’s revenue was up 29.9% compared to the same quarter last year. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of research reports. BTIG Research boosted their price objective on Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. Royal Bank Of Canada boosted their price target on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Barclays upped their price objective on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Evercore ISI assumed coverage on shares of Insulet in a research report on Tuesday, December 16th. They set an “outperform” rating and a $370.00 target price on the stock. Finally, Wolfe Research upped their price target on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $375.05.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.